Medincell Valuation
| MEDCL Stock | EUR 18.10 0.02 0.11% |
At this time, the firm appears to be overvalued. Medincell SA secures a last-minute Real Value of €16.68 per share. The latest price of the firm is €18.1. Our model forecasts the value of Medincell SA from analyzing the firm fundamentals such as Return On Asset of -0.4, current valuation of 180.29 M, and Shares Owned By Insiders of 47.40 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Medincell's price fluctuation is not too volatile at this time. Calculation of the real value of Medincell SA is based on 3 months time horizon. Increasing Medincell's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Medincell's intrinsic value may or may not be the same as its current market price of 18.10, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 18.1 | Real 16.68 | Hype 18.1 | Naive 17.12 |
The intrinsic value of Medincell's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Medincell's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Medincell SA helps investors to forecast how Medincell stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medincell more accurately as focusing exclusively on Medincell's fundamentals will not take into account other important factors: Medincell Total Value Analysis
Medincell SA is now projected to have takeover price of 180.29 M with market capitalization of 215.89 M, debt of 16.25 M, and cash on hands of 5 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Medincell fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
180.29 M | 215.89 M | 16.25 M | 5 M |
Medincell Investor Information
About 47.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.12. Medincell SA had not issued any dividends in recent years. Based on the analysis of Medincell's profitability, liquidity, and operating efficiency, Medincell SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Medincell Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Medincell has an asset utilization ratio of 9.23 percent. This connotes that the Company is making €0.0923 for each dollar of assets. An increasing asset utilization means that Medincell SA is more efficient with each dollar of assets it utilizes for everyday operations.Medincell Ownership Allocation
Medincell SA maintains a total of 25.22 Million outstanding shares. Medincell SA holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Medincell Profitability Analysis
The company reported the revenue of 4.09 M. Net Loss for the year was (24.81 M) with profit before overhead, payroll, taxes, and interest of 4.09 M.About Medincell Valuation
The stock valuation mechanism determines Medincell's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Medincell SA based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Medincell. We calculate exposure to Medincell's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Medincell's related companies.It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. MEDINCELL is traded on Paris Stock Exchange in France.
8 Steps to conduct Medincell's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Medincell's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Medincell's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Medincell's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Medincell's revenue streams: Identify Medincell's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Medincell's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Medincell's growth potential: Evaluate Medincell's management, business model, and growth potential.
- Determine Medincell's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Medincell's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Medincell Stock Analysis
When running Medincell's price analysis, check to measure Medincell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medincell is operating at the current time. Most of Medincell's value examination focuses on studying past and present price action to predict the probability of Medincell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medincell's price. Additionally, you may evaluate how the addition of Medincell to your portfolios can decrease your overall portfolio volatility.